Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Vemurafenib plus cobimetinib achieves significant progression-free survival in melanoma

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 29.09.14
Views: 1737

Prof Grant McArthur - Peter MacCallum Cancer Centre, Melbourne, Australia

At a press conference at ESMO 2014, Prof McArthur presents the results of a phase III trial which found that combination therapy with both BRAF inhibitor vemurafenib and MEK inhibitor cobimetinib achieved greater progression-free survival and response rates than vemurafenib plus placebo in BRAF-mutation positive melanoma.

Read the news story  and watch the interview for more.

Related videos

follow us

War on Cancer 2018

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation